Glenmark gets DCGI nod for favipiravir for treatment of Covid patients – Times of India: NEW DELHI: Drug agency Glenmark Pharmaceuticals on Friday mentioned it has obtained approval from the Indian drug regulator to launch oral antiviral drug favipiravir for therapy of delicate to average COVID-19 sufferers within the nation.

Glenmark gets DCGI nod for favipiravir for treatment of Covid patients – Times of India

It’s for restricted emergency use in India. Restricted use entails accountable medicine use the place each affected person will need to have signed knowledgeable consent earlier than therapy initiation, Glenmark Prescription drugs mentioned in an announcement.
The corporate has obtained the manufacturing and advertising and marketing approval from Drugs Controller General of India (DCGI) to launch favipiravir for the therapy of delicate to average COVID-19 sufferers, it mentioned.
Extra on Covid-19

“This approval has been granted primarily based on analysis of information and in session with the Topic Knowledgeable Committee, as a part of accelerated approval course of, contemplating the emergency state of affairs and unmet medical want of the COVID-19 outbreak,” Glenmark mentioned.
Shares of Glenmark Prescription drugs closed at Rs 409.10 per scrip on the BSE, up 0.93 per cent from its earlier shut.

LEAVE A REPLY

Please enter your comment!
Please enter your name here